Psychological challenges faced by multidrug-resistant tuberculosis patients: a systematic review

https://doi.org/10.22146/bkm.42989

Qanita Syakiratin(1*), Adik Wibowo(2), Esty Febriani(3)

(1) Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia
(2) Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia
(3) Tuberculosis Advisor Lembaga Kesehatan Nahdlatul Ulama (LKNU), Kramat Raya, Jakarta Pusat
(*) Corresponding Author

Abstract


Purpose: Multidrug-resistant tuberculosis (MDR-TB) patients have few adverse effects due to treatment regimens, including psychological side effects that play an important role in the successful MDR-TB management. This study was aimed to identify MDR-TB patients’ challenges within the context of psychological issues and to determine suitable intervention to address psychological problems in MDR-TB patients.

Method: We conducted a systematic review as PRISMA guidelines using databases PubMed, ProQuest, ScienceDirect, Scopus, and Portal Garuda to search for all related articles. From studies identified, 10 were included in the final analysis.

Results: It was found that all studies have documented a range of psychological challenges faced by MDR-TB patients that were depression, anxiety, suicidal tendencies and common issues reported in the studies.

Conclusion: Three main strategies can be implemented in every country to address MDR-TB adverse effects and scale-up MDR-TB treatment efficacy. These strategies require high levels of support from health workers and family member which has an important role in the treatment process.


Keywords


adverse effects; multidrug-resistant tuberculosis; psychological

Full Text:

PDF


References

  1. WHO. Global Tuberculosis Report 2018. World Health Organization; 2018.
  2. World Health Organization. Global Tuberculosis Report 2017. 2017.
  3. Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK. Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia. Patient Prefer Adherence. 2016;10: 2369–2377.
  4. World Health Organization. Guidelines for Surveillance of Drug Resistance in Tuberculosis. 2015.
  5. Walker IF, Baral SC, Wei X, Huque R, Khan A, Walley J, et al. Multidrug-resistant tuberculosis treatment programmes insufficiently consider comorbid mental disorders. Int J Tuberc Lung Dis. 2017;21: 603–609.
  6. Morris MD, Quezada L, Bhat P, Moser K, Smith J, Perez H, et al. Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient’s perspective [Internet]. The International Journal of Tuberculosis and Lung Disease. 2013. pp. 954–960. doi:10.5588/ijtld.12.0480
  7. Rahmawati RN, Pranggono EH, Ruslami R. Clinical Characteristics and Side Effects of Multidrug Resistant Tuberculosis Therapy at Top Referral Hospital West Java Indonesia [Internet]. althea medical journal. 2016. pp. 526–532. doi:10.15850/amj.v3n4.934
  8. Yang TW, Park HO, Jang HN, Yang JH, Kim SH, Moon SH, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea [Internet]. Medicine. 2017. p. e7482. doi:10.1097/md.0000000000007482
  9. Stosic M, Vukovic D, Babic D, Antonijevic G, Foley KL, Vujcic I, et al. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: a case-control study [Internet]. BMC Public Health. 2018. doi:10.1186/s12889-018-6021-5
  10. Khanal S, Elsey H, King R, Baral SC, Bhatta BR, Newell JN. Development of a Patient-Centred, Psychosocial Support Intervention for Multi-Drug-Resistant Tuberculosis (MDR-TB) Care in Nepal. PLoS One. 2017;12: e0167559.
  11. Roba AA, Dasa TT, Weldegebreal F, Asfaw A, Mitiku H, Teklemariam Z, et al. Tuberculosis patients are physically challenged and socially isolated: A mixed methods case-control study of Health Related Quality of Life in Eastern Ethiopia. PLoS One. 2018;13: e0204697.
  12. D Das HS. Cycloserine induced depression in a case of multidrug resistant tuberculosis. WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES. 2017;6: 1069–1073.
  13. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4: 1.
  14. Ahmad N, Javaid A, Sulaiman SAS, Basit A, Afridi AK, Jaber AAS, et al. Effects of Multidrug Resistant Tuberculosis Treatment on Patients’ Health Related Quality of Life: Results from a Follow Up Study [Internet]. PLOS ONE. 2016. p. e0159560. doi:10.1371/journal.pone.0159560
  15. Isaakidis P, Rangan S, Pradhan A, Ladomirska J, Reid T, Kielmann K. “I cry every day”: experiences of patients co-infected with HIV and multidrug-resistant tuberculosis. Trop Med Int Health. 2013;18: 1128–1133.
  16. Alfiyani L, Masters Program in Public Health, Sebelas Maret University, Rahardjo SS, Murti B, Faculty of Medicine, et al. Biopsychosocial Determinants of Multi Drug Resistant Tuberculosis in Surakarta [Internet]. Journal of Epidemiology and Public Health. 2017. pp. 255–266. doi:10.26911/jepublichealth.2017.02.03.07
  17. Thomas BE, Shanmugam P, Malaisamy M, Ovung S, Suresh C, Subbaraman R, et al. Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: A Systematic Review. PLoS One. 2016;11: e0147397.
  18. Workicho A, Kassahun W, Alemseged F. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study. Infect Drug Resist. 2017;10: 91–96.
  19. Tola HH, Shojaeizadeh D, Garmaroudi G, Tol A, Yekaninejad MS, Ejeta LT, et al. Psychological distress and its effect on tuberculosis treatment outcomes in Ethiopia [Internet]. Global Health Action. 2015. p. 29019. doi:10.3402/gha.v8.29019
  20. Das M, Isaakidis P, Van den Bergh R, Kumar AMV, Nagaraja SB, Valikayath A, et al. HIV, multidrug-resistant TB and depressive symptoms: when three conditions collide. Glob Health Action. 2014;7: 24912.
  21. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization; 2014.
  22. Khan KS, Kunz R, Kleijnen J, Antes G. Five steps to conducting a systematic review [Internet]. JRSM. 2003. pp. 118–121. doi:10.1258/jrsm.96.3.118
  23. Kastien-Hilka T, Abulfathi A, Rosenkranz B, Bennett B, Schwenkglenks M, Sinanovic E. Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis– a systematic review of global literature with focus on South Africa [Internet]. Health and Quality of Life Outcomes. 2016. doi:10.1186/s12955-016-0442-6
  24. Vega P, Sweetland A, Acha J, Castillo H, Guerra D, Smith Fawzi MC, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8: 749–759.
  25. Otu AA, Offor JB, Ekpor IA, Olarenwaju O. New-Onset Psychosis in a Multi-Drug Resistant Tuberculosis Patient on Cycloserine in Calabar, Nigeria: A Case Report [Internet]. Tropical Journal of Pharmaceutical Research. 2014. p. 303. doi:10.4314/tjpr.v13i2.21



DOI: https://doi.org/10.22146/bkm.42989

Article Metrics

Abstract views : 442 | views : 183

Refbacks

  • There are currently no refbacks.




Copyright (c) 2019 Berita Kedokteran Masyarakat

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Berita Kedokteran Masyarakat ISSN 0215-1936 (PRINT), ISSN: 2614-8412 (ONLINE).

Indexed by:


Web
Analytics Visitor Counter